NCT07436143 Effects of Posture and Quality of Life in Duchenne Muscular Dystrophy Children
| NCT ID | NCT07436143 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Riphah International University |
| Condition | Child, Only |
| Study Type | INTERVENTIONAL |
| Enrollment | 33 participants |
| Start Date | 2025-10-27 |
| Primary Completion | 2026-02-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 33 participants in total. It began in 2025-10-27 with a primary completion date of 2026-02-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Duchenne muscular dystrophy (DMD) is an X-linked recessive neuromuscular disorder predominantly affecting boys and men, with an estimated incidence of 1 in 3,800 to 1 in 6,200 live male births. This condition leads to progressive muscle weakness due to the absence of the dystrophin protein, which is essential for maintaining muscle cell integrity. Symptoms and functional impairments typically become apparent by the age of two, and individuals with DMD have an average life expectancy of around 28 years. Treatment is generally multifaceted, focusing on enhancing quality of life (QOL) and postural control. The Alexander technique is employed to improve QOL and postural tone, as well as to modify body schema, with reported benefits from these changes. This method leverages spatial attention and executive functions that influence basic motor skills through targeted attention, intention, and haptic communication, thereby enhancing the QOL and postural control of the upper limbs. The aim of the study is to determine the effects of Alexander's technique on postural control of upper limb and quality of life in children with duchenne muscular dystrophy.
Eligibility Criteria
Inclusion Criteria: * Children suffering from duchenne muscular dystrophy,age between 5 to 9 Exclusion Criteria: * Children with metabolic disorder * Children with accidental disorder * Children with recent of surgery * Children with mentally retard
Contact & Investigator
Muhammad Hassan Tahir, MS-PT
PRINCIPAL INVESTIGATOR
Riphah International University
Frequently Asked Questions
Who can join the NCT07436143 clinical trial?
This trial is open to male participants only, aged 5 Years or older, up to 9 Years, studying Child, Only. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07436143 currently recruiting?
Yes, NCT07436143 is actively recruiting participants. Contact the research team at imran.amjad@riphah.edu.pk for enrollment information.
Where is the NCT07436143 trial being conducted?
This trial is being conducted at Lahore, Pakistan.
Who is sponsoring the NCT07436143 clinical trial?
NCT07436143 is sponsored by Riphah International University. The principal investigator is Muhammad Hassan Tahir, MS-PT at Riphah International University. The trial plans to enroll 33 participants.